Ascendis Pharma Stock Forecast

Stock Price Forecast

According to 18 analysts polled by S&P Global, Ascendis Pharma stock has a consensus rating of "Strong Buy" and an average price target of $293.03. The average 1-year stock price forecast is 26.95% higher than the current stock price, while the lowest is $249.34 (+8.02%) and the highest is $349.67 (+51.48%).

Price Target: $293.03 (+26.95%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$249.34	$293.03	$289.41	$349.67
Change	+8.02%	+26.95%	+25.38%	+51.48%

Analyst Ratings

The average analyst rating for Ascendis Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Apr '26	May '26	Jun '26
Strong Buy	3	13	14
Buy	1	4	4
Hold	0	0	0
Sell	0	0	0
Strong Sell	0	0	0
Total	4	17	18

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Jessica Fye J.P. Morgan	J.P. Morgan	Buy Reiterates n/a	Buy	Reiterates	n/a	n/a	Jun 18, 2026
Derek Archila Wells Fargo	Wells Fargo	Buy Maintains $450 → $326	Buy	Maintains	$450 → $326	+41.23%	Jun 17, 2026
Tazeen Ahmad Bank of America Securities	Bank of America Securities	Buy Maintains $288	Buy	Maintains	$288	+24.77%	Jun 16, 2026
Leland Gershell Oppenheimer	Oppenheimer	Buy Reiterates $262	Buy	Reiterates	$262	+13.50%	Jun 15, 2026
Yun Zhong Wedbush	Wedbush	Buy Maintains $273	Buy	Maintains	$273	+18.27%	Jun 15, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

1.34B

from 720.13M

85.76%

from 720.13M

Revenue Next Year

1.94B

from 1.34B

45.17%

from 1.34B

EPS This Year

11.44

from -

EPS Next Year

9.42

from 11.44

-17.63%

from 11.44

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Jan 1, 2023	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	7.78M	51.17M	266.72M	363.64M	720.13M	1.34B
Revenue Growth	11.87%	557.93%	421.20%	36.34%	98.03%	85.76%
Gross Profit	4.26M	39.04M	222.32M	319.38M	625.22M	1.20B
Gross Margin	54.71%	76.28%	83.36%	87.83%	86.82%	89.63%
Operating Income	-451.79M	-561.81M	-455.54M	-278.76M	-136.27M	323.77M
Net Income	-383.58M	-583.19M	-481.45M	-378.08M	-228.03M	916.58M
EPS	-	-	-	-	-	11.44
Forward PE	-	-	-	-	-	17.61
Free Cash Flow	-281.90M	-156.42M	-332.95M	-200.32M	164.71M	349.00M
No. Analysts	-	-	-	-	-	15

EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is EUR.

Revenue Forecast

Revenue	2026	2027	2028
High	1.6B
Avg	1.3B
Low	1.3B

Revenue Growth

Revenue Growth	2026	2027	2028
High	115.3%
Avg	85.8%
Low	75.0%

EPS Forecast

EPS	2026	2027	2028
High	16.69
Avg	11.44
Low	2.13

EPS Growth

EPS Growth	2027	2028
High	2.3%
Avg	-17.6%
Low	-33.9%